Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,068.17
-6.51 (-0.61%)
Streaming Delayed Price
Updated: 12:10 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Today 12:10 EST
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
Today 11:44 EST
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...
Via
MarketMinute
Topics
Economy
Intellectual Property
S&P 500 Tests Critical Support Levels as 2026 Kicks Off Under Technical Pressure
Today 11:42 EST
The S&P 500 (INDEXSP:.INX) entered the new year on a tenuous footing, grappling with a rare four-session losing streak that capped off an otherwise stellar 2025. After finishing the final trading day...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
↗
Today 11:15 EST
Via
Benzinga
Alphabet’s Golden Year: Inside the 2025 Rally and the Future of the AI Giant
Today 10:12 EST
As we enter 2026, the narrative surrounding the world’s most dominant information gateway has shifted from one of existential threat to unprecedented strength. Alphabet Inc. (NASDAQ: GOOGL / GOOG) has...
Via
PredictStreet
Topics
Artificial Intelligence
Initial Public Offering
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
January 01, 2026
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...
Via
TokenRing AI
Topics
Artificial Intelligence
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
January 01, 2026
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...
Via
TokenRing AI
Topics
Artificial Intelligence
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
January 01, 2026
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...
Via
MarketMinute
Topics
Intellectual Property
Navigating the Neutral Rate: Wall Street's 2026 Outlook Forecasts Growth Amidst AI Maturity
January 01, 2026
As the opening bell prepares to ring for the first time in 2026, the American investor finds themselves at a unique crossroads of technological maturation and economic normalization. Following a robust...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
January 01, 2026
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...
Via
PredictStreet
Topics
Economy
Lawsuit
World Trade
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
↗
January 01, 2026
These two companies have very different risk-reward profiles.
Via
The Motley Fool
Topics
Artificial Intelligence
Where Will Pfizer Be in 5 Years?
↗
December 31, 2025
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.
Via
The Motley Fool
Topics
Intellectual Property
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
December 31, 2025
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...
Via
MarketMinute
Topics
Economy
Intellectual Property
Law Enforcement
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026
↗
December 31, 2025
Via
MarketBeat
So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO.
↗
December 31, 2025
Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.
Via
Investor's Business Daily
Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine
December 31, 2025
The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI...
Via
TokenRing AI
Topics
Artificial Intelligence
Bonds
The 2026 Earnings Gauntlet: Can Corporate Profits Justify Wall Street's High-Wire Act?
December 31, 2025
As the clock strikes midnight on December 31, 2025, the U.S. stock market stands at a historic crossroads. The S&P 500 has closed the year at record highs, fueled by a relentless surge in artificial...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
December 31, 2025
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Could This Potential Move Boost Eli Lilly's Prospects?
↗
December 31, 2025
The stock already looks unstoppable, and this move won't hurt its momentum.
Via
The Motley Fool
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
↗
December 31, 2025
Via
MarketBeat
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report
↗
December 31, 2025
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.
Via
Stocktwits
Topics
Economy
Government
The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier
December 30, 2025
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the...
Via
TokenRing AI
Topics
Artificial Intelligence
S&P 500 Hovers at the Flatline: A Masterclass in Market Resilience or the Quiet Before a 2026 Storm?
December 30, 2025
As the sun sets on 2025, the S&P 500 is holding its breath. In a trading session characterized by thin holiday volume and a notable absence of institutional conviction, the benchmark index spent much...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Why Novo Nordisk Stock Dropped on Monday
↗
December 30, 2025
The cost of Wegovy is about to decrease significantly in a populous overseas market.
Via
The Motley Fool
Topics
Intellectual Property
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...
Via
MarketMinute
Topics
ETFs
Economy
World Trade
The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility
December 30, 2025
As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
ETFs
Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High?
↗
December 30, 2025
History is clear about what investors should do heading into the new year.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Stocks
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
December 30, 2025
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Top gainers and losers in the S&P500 index during Monday's after-hours session.
↗
December 29, 2025
Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
